Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2007

Lipomics and Duke Collaborate on Pharmacometabolomic Marker Research

  • Lipomics Technologies and Duke University signed a deal to identify pharmacometabolomic markers in various clinical areas. Initial research will focus on CNS disorders such as schizophrenia and depression and cardiovascular diseases in terms of response to statins.

    Under this two-year agreement, Lipomics will provide Duke technology and services for biomarker research, validation, and analysis. In return, Lipomics has the option to license diagnostic rights on all such markers developed.

    Lipomics’ platform and technologies relating to lipid profiles and data transfer and interpretation services will be used by the Duke scientists.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »